Emerging Vaccines – Landscape & Forecast – Disease Landscape & Forecast

The implementation of vaccination programs has had a revolutionary impact on global public health, not only leading to dramatic reductions in the incidence of infectious diseases but also reducing childhood and adult mortality and drastically improving the quality of life worldwide. Individuals can receive a wide range of vaccinations throughout their life, preventing infections and the diseases associated with long-term chronic infections. Although vaccination guidelines may offer strong recommendations for certain vaccines, others are administered at the discretion of the prescribing physician and the patient. As such, commercial opportunity exists for vaccines that can offer meaningful advantages over current agents, and both the adult and pediatric segments of the vaccines market remain attractive areas for the development of new prophylactic options. This content will include coverage of current and emerging COVID-19 vaccines and assess the impact of the COVID-19 pandemic on the vaccines market.

QUESTIONS ANSWERED

  • What are the sizes of the populations eligible for key vaccination programs in the G7?
  • Who are the key decision makers for vaccine purchasing and administration, and how does this group vary by geography?
  • What are the key drivers of brand preference in a given vaccine market?
  • Which pathogens are associated with the most unmet need in terms of the development of a new or improved vaccine? Which patient pools do experts anticipate will be eligible for these vaccines?
  • How will the current vaccines pipeline fulfill areas of unmet need in this market?
  • How will key current and emerging vaccines perform commercially?
  • How has the COVID-19 pandemic impacted the use of current vaccines?

PRODUCT DESCRIPTION

Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

SOLUTION ENHANCEMENT

Disease Landscape & Forecast will feature continuous updates in 2021 to provide timely insights and analyses as meaningful indication-specific news and events unfold.

GEOGRAPHIES: United States, EU5, Japan

PRIMARY RESEARCH: Approximately 15 country-specific interviews with thought-leading infectious disease specialists; supported by survey data collected for this and other Clarivate research.

EPIDEMIOLOGY: Diagnosed events of emerging vaccines by country, segmented by key vaccines (human papilloma virus, herpes zoster virus, meningococcus, pneumococcus, seasonal influenza, hepatitis B virus, respiratory syncytial virus, COVID-19).

FORECAST: 10-year, annualized, vaccine-level sales and patient share of key vaccines through 2030, segmented by vaccine, geography, and key indications.

EMERGING THERAPIES: Registered / preregistered: 4; Phase III: 11; Phase II: 23; Phase I: 18.

Table of contents

  • Emerging Vaccines - Landscape & Forecast - Disease Landscape & Forecast
    • Key Updates
      • Q2 2022
        • April 2022
      • Q1 2022
        • March 2022
        • February 2022
        • January 2022
        • April 2022
      • Q4 2021
        • December 2021
      • Q3 2021
        • September 2021
        • August 2021
        • July 2021
      • Q2 2021
        • June 2021
        • May 2021
        • April 2021
      • Q1 2021
        • March 2021
        • January 2021
    • Key Findings
      • Emerging Vaccines Key Findings - December 2021
        • March 2021
        • January 2021
    • Market Outlook
      • Key Findings
        • Market Overview
        • SWOT Analysis
      • Market Drivers and Constraints
        • What Factors Are Driving the Market for Vaccines?
        • What Factors Are Constraining the Market for Vaccines?
      • Segment-Specific Trends
        • Major-Market Sales of Vaccines Against Human Papillomavirus, 2020-2030
        • Major-Market Sales of Vaccines Against Herpes Zoster, 2020-2030
        • Major-Market Sales of Vaccines Against Meningococcus B, 2020-2030
        • Major-Market Sales of Vaccines Against Meningococcus ACWY, 2020-2030
        • Major-Market Sales of Vaccines Against Pneumococcus, 2020-2030
        • Major-Market Sales of Vaccines Against Seasonal Influenza, 2020-2030
        • Major-Market Sales of Vaccines Against Hepatitis B Virus, 2020-2030
        • COVID-19 Vaccines
        • Major-Market Sales of Vaccines Against COVID-19 Virus, 2020-2030
    • Forecast
      • Market Forecast Assumptions
      • Market Forecast Dashboard
    • Vaccine Technologies
      • Immunology and Vaccine-Preventable Diseases
        • Active Immunity
          • Classification of Vaccines
            • Live Attenuated Vaccines
              • Inactivated Vaccines
                • Polysaccharide Vaccines
                  • Vaccines Based on Bacterial Proteins, Polysaccharides, and Protein-Conjugated Polysaccharides
                    • Recombinant Vaccines
                      • Adjuvants
                        • Genetic Vaccines
                          • DNA Vaccines
                          • mRNA Vaccine
                      • Epidemiology
                        • Key Findings
                          • Epidemiology Populations
                            • Definition
                            • Methods
                            • Sources Used for the Population Eligible for the RSV Vaccine
                            • Total Population Eligible for the RSV Vaccine: 2020-2030 (Thousands)
                            • Definition
                            • Methods
                            • Sources Used for the Population Eligible for the HBV Vaccine
                            • Total Population Eligible for the Hepatitis B Vaccine: 2020-2030 (Thousands)
                            • Disease Definition
                            • Methods
                            • Sources Used for the Population Eligible for the Human Papillomavirus Vaccine
                            • Total Population Eligible for the Human Papillomavirus Vaccine: 2020-2030 (Thousands)
                            • Disease Definition
                            • Methods
                            • Sources Used for the Population Eligible for the Shingles Vaccine
                            • Total Population Eligible for the Shingles Vaccine: 2020-2030 (Thousands)
                            • Disease Definition
                            • Methods
                            • Sources Used for the Population Eligible for the Influenza Vaccine
                            • Total Population Eligible for the Influenza Vaccine: 2020-2030 (Thousands)
                            • Disease Definition
                            • Methods
                            • Sources Used for the Population Eligible for the Pneumococcal Vaccine
                            • Total Population Eligible for the Pneumococcal Vaccine: 2020-2030 (Thousands)
                            • Disease Definition
                            • Methods
                            • Sources Used for the Population Eligible for the Meningococcal B Vaccine
                            • Total Population Eligible for the Meningococcal B Vaccine: 2020-2030 (Thousands)
                            • Disease Definition
                            • Methods
                            • Sources Used for the Population Eligible for the Meningococcal A, C, W, and Y Vaccine
                            • Total Population Eligible for the Meningococcal A, C, W, and Y Vaccine: 2020-2030 (Thousands)
                            • Definition
                            • Methods
                            • Sources Used for the Population Eligible for the COVID-19 Vaccine
                            • Total Population Eligible for the COVID-19 Vaccine: 2020-2030 (Thousands)
                            • Sources Used for Vaccination Rates
                            • Number of Vaccinated Patients: 2020-2030 (in Thousands)
                        • Current Treatment
                          • Key Findings
                            • Treatment Goals
                              • Key Endpoints Used in Clinical Trials of Vaccines
                            • Key Current Therapies
                              • Overview
                              • Mechanism of Action of Key Current Vaccines
                              • Current Vaccines
                              • Advantages and Disadvantages of Gardasil 9
                              • Advantages and Disadvantages of Gardasil
                              • Advantages and Disadvantages of Cervarix
                              • Expert Insight: HPV Vaccines
                              • Vaccination Guidelines
                              • Country-Specific HPV Vaccination Guidelines
                              • Factors Influencing Vaccine Selection in HPV
                              • Advantages and Disadvantages of Prevnar 13
                              • Advantages and Disadvantages of Pneumovax 23
                              • Prevnar 20
                              • Advantages and Disadvantages of Prevnar 20
                              • Vaxneuvance
                              • Advantages and Disadvantages of Vaxneuvance
                              • Expert Insight: Pneumococcal Vaccines
                              • Vaccination Guidelines
                              • Country-Specific Pneumococcal Vaccination Guidelines
                              • Factors Influencing Vaccine Selection for Pneumococcus
                              • Meningococcal Vaccines
                              • Advantages and Disadvantages of Menveo
                              • Advantages and Disadvantages of Menactra
                              • Advantages and Disadvantages of Nimenrix
                              • Menquadfi
                              • Advantages and Disadvantages of Menquadfi
                              • Advantages and Disadvantages of Bexsero
                              • Advantages and Disadvantages of Trumenba
                              • Expert Insight: Meningococcal Vaccines
                              • Vaccination Guidelines
                              • Country-Specific Meningococcal Vaccination Guidelines
                              • Factors Influencing Vaccine Selection for Meningococcus
                              • Advantages and Disadvantages of Fluzone
                              • Advantages and Disadvantages of Flulaval
                              • Advantages and Disadvantages of Fluarix
                              • Current Minor Vaccines Used for Seasonal Influenza
                              • Expert Insight: Seasonal Influenza Vaccines
                              • Vaccination Guidelines
                              • Country-Specific Seasonal Influenza Vaccination Guidelines
                              • Factors Influencing Vaccine Selection for Seasonal Influenza
                              • Advantages and Disadvantages of Engerix-B
                              • Advantages and Disadvantages of Recombivax HB / HBVaxPRO
                              • Advantages and Disadvantages of Heplisav-B
                              • Sci-B-Vac (PreHevbrio)
                              • Expert Insight: Hepatitis B Virus Vaccines
                              • Vaccination Guidelines
                              • Factors Influencing Vaccine Selection for Hepatitis B Virus
                              • Country-Specific Hepatitis B Virus Vaccination Guidelines
                              • Advantages and Disadvantages of Comirnaty
                              • Advantages and Disadvantages of Spikevax
                              • Advantages and Disadvantages of Vexzevria / AZD1222
                              • Advantages and Disadvantages of Johnson & Johnson COVID-19 Vaccine
                              • Expert Insight: COVID-19 Vaccines
                              • Vaccination Guidelines
                              • Factors Influencing Vaccine Selection for COVID-19
                              • Advantages and Disadvantages of Shingrix
                              • Advantages and Disadvantages of Zostavax
                              • Vaccination Guidelines
                              • Country-Specific HZ Vaccination Guidelines
                              • Factors Influencing Vaccine Selection for Herpes Zoster
                          • Unmet Need Overview
                            • Current and Future Attainment of Unmet Needs for Vaccines
                              • Top Unmet Needs for Vaccines: Current and Future Attainment
                              • Expert Insight: Unmet Need for Vaccines
                          • Emerging Therapies
                            • Key Findings
                              • Key Emerging Therapies
                                • Key Vaccines in Development
                                • Estimated Launch Dates of Key Emerging Vaccines
                                • Oral Flu Vaccine Profile
                                • Analysis of the Clinical Development Program for Oral Flu Vaccine
                                • Expectations for Launch and Sales Opportunity of Oral Flu Vaccine for Seasonal Influenza
                                • M-001 Profile
                                • M-001 Clinical Development
                                • Expectations for Launch and Sales Opportunity of M-001 for Seasonal Influenza
                                • NasoVAX Profile
                                • Analysis of the Clinical Development Program for NasoVAX
                                • Expectations for Launch and Sales Opportunity of NasoVAX for Seasonal Influenza
                                • NanoFlu Profile
                                • Analysis of the Clinical Development Program for NanoFlu
                                • Expectations for Launch and Sales Opportunity of NanoFlu for Seasonal Influenza
                                • ResVax Profile
                                • Analysis of the Clinical Development for ResVax
                                • Expectations for Launch and Sales Opportunity of ResVax for RSV
                                • MVA-BN RSV Profile
                                • Analysis of the Clinical Development Program for MVA-BN RSV
                                • Expectations for Launch and Sales Opportunity of MVA-BN-RSV for RSV
                                • JNJ-64400141 Profile
                                • Analysis of the Clinical Development Program for JNJ-64400141
                                • Expectations for Launch and Sales Opportunity of JNJ-64400141
                                • PF-06928316 Profile
                                • Analysis of the Clinical Development Program for PF-06928316
                                • Expectations for Launch and Sales Opportunity of PF-06928316
                                • GSK-3888550A Profile
                                • Analysis of the Clinical Development Program for GSK-3888550A
                                • Expectations for Launch and Sales Opportunity of GSK-3888550A
                                • GSK-3844766A Profile
                                • Analysis of the Clinical Development Program for GSK-3844766A
                                • Expectations for Launch and Sales Opportunity of GSK-3844766A
                                • Sci-B-Vac Profile
                                • Analysis of the Clinical Development Program for Sci-B-Vac
                                • Expectations for Launch and Sales Opportunity of Sci-B-Vac for HBV
                                • Meningococcal Vaccines
                                • GSK-3536819A
                                • GSK-3536819A Profile
                                • Analysis of the Clinical Development Program for GSK-3536819A
                                • Expectations for Launch and Sales Opportunity of GSK-3536819A
                                • PF-06886992
                                • Analysis of the Clinical Development Program for PF-06886992
                                • Expectations for Launch and Sales Opportunity of PF-06886992
                                • COVID-19 Vaccines
                                • NVX-CoV2373
                                • NVX-CoV2373 Profile
                                • Analysis of the Clinical Development Program for NVX-CoV2373
                                • Expectations for Launch and Sales Opportunity of NVX-CoV2373 for COVID-19
                                • Coronavac
                                • Analysis of the Clinical Development Program for Coronavac
                                • Expectations for Launch and Sales Opportunity of Coronavac for COVID-19
                                • SP-0253
                                • SP-0253 Profile
                                • Analysis of the Clinical Development Program for SP-0253
                                • Expectations for Launch and Sales Opportunity of SP-0253 for COVID-19
                                • VLA-2001
                                • VLA-2001 Profile
                                • Analysis of the Clinical Development Program for VLA-2001
                                • Expectations for Launch and Sales Opportunity of VLA-2001 for COVID-19
                                • Additional Mid- to Late-Phase Emerging Vaccines of Note
                              • Early-Phase Pipeline Analysis
                                • Select Vaccines in Early-Phase Development
                            • Access & Reimbursement Overview
                              • Region-Specific Reimbursement Practices
                                • Key Market Access Considerations for Vaccines: United States
                                • General Reimbursement Environment: United States
                                • Key Market Access Considerations for Vaccines: EU5
                                • General Reimbursement Environment: EU5
                                • Key Market Access Considerations for Vaccines: Japan
                                • General Reimbursement Environment: Japan
                            • Appendix
                              • Vaccines Bibliography